BusinessNeothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous FatBy Nasdaq OMXJun 26, 2017, 12:01 PM UTC
BusinessNeothetics Provides Business Update and Reports First Quarter 2017 Financial ResultsBy Nasdaq OMXMay 11, 2017, 12:00 PM UTC
BusinessNeothetics to Provide a Business Update and Release First Quarter 2017 Financial Results Thursday, May 11th, 2017By Nasdaq OMXMay 4, 2017, 12:01 PM UTC
BusinessNeothetics Announces Issuance by USPTO of Eighth Patent Directed to LIPO-202 Lead Clinical AssetBy Nasdaq OMXApr 5, 2017, 12:00 PM UTC
BusinessNeothetics to Present at the 16th Annual Needham Healthcare ConferenceBy Nasdaq OMXMar 29, 2017, 12:00 PM UTC
BusinessNeothetics Provides Business Update and Reports Fourth Quarter 2016 Financial ResultsBy Nasdaq OMXMar 23, 2017, 12:00 PM UTC
BusinessNeothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous FatBy Nasdaq OMXMar 20, 2017, 12:00 PM UTC
BusinessNeothetics to Provide a Business Update and Release Fourth Quarter 2016 Financial Results Thursday, March 23, 2017By Nasdaq OMXMar 16, 2017, 12:00 PM UTC
